IntelGenx Technologies Corp. (IGXT) EPS Estimated At $-0.02 as of May, 10

May 3, 2018 - By Sarah Harris

IntelGenx Technologies Corp. (OTCMKTS:IGXT) Corporate Logo

Investors expect IntelGenx Technologies Corp. (OTCMKTS:IGXT)’s quarterly earnings on May, 10., Zacks reports. EPS of $-0.02 is 100.00 % down from 2017’s $-0.01 EPS. After $-0.02 EPS was reported last quarter, analysts now see EPS growth of 0.00 % for IntelGenx Technologies Corp.. The stock increased 6.86% or $0.042515 during the last trading session, touching $0.662515.Currently IntelGenx Technologies Corp. is after 0.00% change in last May 3, 2017. IGXT has shares volume. IGXT underperformed by 11.55% the S&P 500.

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market.The firm is valued at $44.87 million. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines.Last it reported negative earnings. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.